PLE-THU-17

Proteome centric precision medicine: defining and treating pathological diversity

J Van Eyk

Advanced Clinical Biosystems Research Institute, Cedar Sinai Medical Center, Los Angeles, USA

Precision medicine requires success in two intertwined aspects: precision therapy and personalized medicine. Precision therapy is being able to effectively treat the right disease; to have therapies that target for the correct pathological pathways. Personalized medicine requires diagnosing a specific individual's disease based on accurate assessment their complex health and pathological status. Our underlying premise is that an individual's baseline proteome reflects their past and present and thus, will dictate their future health and disease. Thus, the crux of precision medicine will be the identification and precise quantification of proteins and their modified forms. We will present data to support the notion that an individual's baseline proteome dictates the manifestation of their disease, its progression and their response to therapy. Our studies on 100s of individual's samples with different cardiovascular diseases have provided key insights on the effect of biological and pathological variability. This work has led us to consider the need for continuous patent-centric health screening at the population level. We will share our work on developing technical pipelines for health screening that reduces the barriers around sex, age and social economic status. This will/has required development of microsampling device, point of service devices, pathways for client data return and specific clinical grade assays. We have begun down this path with production of system suitability and quality control measures, assays and volumetric sampling device and will discuss the remaining challenges involved and requirement.